

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 30 September 2016

- Share placement to cornerstone investor finalised, delivering \$500,000 additional capital
- Expect \$1.1 m R & D Tax Incentive refund in the December quarter
- FDA over the counter clearance for PeriCoach
- PeriCoach granted patent protection in China
- AutoStart Burette granted US Patent
- Cash outflow reduced to \$794k
- Cash balance as of 30 September, \$952k

28 October 2016: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System, has today released its Appendix 4C - Quarterly Cashflow report for period ending 30 September 2016.

During the quarter, the company completed a placement to its cornerstone investor, INOV8 LLC, in two tranches of \$250,000, bringing the company's cash balance to \$952,000 at the end of the quarter. An estimated \$1.1 million of R&D tax credit is due to be paid in the December quarter.

The total cash outflow reduced to \$794,000 in line with the company's ongoing cost containment program. Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$19,000.

Operationally the company remains focused on finalising the development of Version 3 of the PeriCoach System. Following receipt of over-the-counter clearance from the United States Food and Drug Administration, which allows the device to be sold without a prescription, the company continues to focus on building awareness and clinical support in the US market. The FDA also provided confirmation that the PeriCoach can be marketed for improved sexual function under general wellness claims. These two events, expand the market opportunity for PeriCoach and adds to the appeal for a potential licensing partner.

A US patent granted for AutoStart® Burette a key step in the commercialisation of the AutoStart infusion system.

Analytica CEO Geoff Daly said: "We are very pleased with the strong vote of confidence in the company with the placement to our cornerstone investor. The company is committed to managing costs and cash burn, while focusing on the business activities which will best support the commercialisation and securing of a licence partner for PeriCoach."

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:





About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Analytica Ltd

ABN

12 006 464 866

Quarter ended ("current quarter")

September 2016

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	19	19
1.2 Payments for		
(a) research and development	(238)	(238)
(b) product manufacturing and operating costs	(24)	(24)
(c) advertising and marketing	(127)	(127)
(d) leased assets		
(e) staff costs	(323)	(323)
(f) administration and corporate costs	(107)	(107)
1.3 Dividends received (see note 3)		
1.4 Interest received	3	3
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)	3	3
1.9 Net cash from / (used in) operating activities	(794)	(794)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(1)	(1)
(b) businesses (see item 10)		
(c) investments		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	(d) intellectual property		
	(e) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment		
	(b) businesses (see item 10)		
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(1)	(1)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	500	500
3.2	Proceeds from issue of convertible notes		
3.3	Proceeds from exercise of share options		
3.4	Transaction costs related to issues of shares, convertible notes or options	(2)	(2)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	498	498

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,254	1,254
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(794)	(794)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1)	(1)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	498	498

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	(5)	(5)
4.6	Cash and cash equivalents at end of quarter	952	952

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	952	1,254
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	952	1,254

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
110
0

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter \$A'000

8. Financing facilities available

Add notes as necessary for an understanding of the position

8.1 Loan facilities

8.2 Credit standby arrangements

8.3 Other (please specify)

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

Income tax return has been lodged and expect a R & D tax incentive refund of \$1.1m.

**Total facility amount
at quarter end
\$A'000**

**Amount drawn at
quarter end
\$A'000**

400

400

9. Estimated cash outflows for next quarter

\$A'000

9.1 Research and development

246

9.2 Product manufacturing and operating costs

109

9.3 Advertising and marketing

112

9.4 Leased assets

9.5 Staff costs

304

9.6 Administration and corporate costs

116

9.7 Other (provide details if material)

9.8 Total estimated cash outflows

887

**10. Acquisitions and disposals of
business entities
(items 2.1(b) and 2.2(b) above)**

Acquisitions

Disposals

10.1 Name of entity

10.2 Place of incorporation or
registration

10.3 Consideration for acquisition or
disposal

10.4 Total net assets

10.5 Nature of business

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:Original signed.....
(Director)

Date: ...28 October 2016.....

Print name: R. Mangelsdorf

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.